2016
DOI: 10.17265/2159-5828/2016.05.005
View full text
|
|
Share
Rahal Lotfi, Joerg George Birkmayer, Ahmed Ghouini

Abstract: Twenty patients with diabetes type-2, aged between 38 and 61 years, with at least one cardiovascular risk factor were divided in two groups (Group-1 included newly diagnosed type 2 diabetic patients without treatment with oral antidiabetic OAD, Group-2: patients with diabetes type 2 under OAD +/-insulin (N = 11)). Patients from both groupswere taking Nicotinamide Adenine Dinucleotide (NADH) Rapid Energy® 80 mg/day in two takes for a period of 56 days. A greater reduction in average fasting glucose and HbA1c af…

expand abstract